YAKHAK HOEJI (약학회지)

The Pharmaceutical Society of Korea (대한약학회)
권호 표지

In vivo Efficacy of LB20304a against Experimental Respiratory Tract Infection in Mice

생쥐의 호흡기 감염에 대한 퀴놀론계 항생제 LB20304a의 치료 효과

  • An, Mi-Jeong (Biotech Research Institute, LG Chem Research Park, LG Chemical Ltd.) ;
  • Kim, Mu-Yong (Biotech Research Institute, LG Chem Research Park, LG Chemical Ltd.) ;
  • Baek, Gyeong-Suk (Biotech Research Institute, LG Chem Research Park, LG Chemical Ltd.) ;
  • Kim, In-Cheol (Biotech Research Institute, LG Chem Research Park, LG Chemical Ltd.) ;
  • Gwak, Jin-Hwan (Biotech Research Institute, LG Chem Research Park, LG Chemical Ltd.)
  • 안미정 (LG화학 기술연구원, 바이오텍연구소) ;
  • 김무용 (LG화학 기술연구원, 바이오텍연구소) ;
  • 백경숙 (LG화학 기술연구원, 바이오텍연구소) ;
  • 김인철 (LG화학 기술연구원, 바이오텍연구소) ;
  • 곽진환 (LG화학 기술연구원, 바이오텍연구소)
  • Published : 1996.08.01
Download PDF
⟨ Previous Next ⟩

Abstract

The therapeutic activity of LB20304a was examined on experimental respiratory tract infection (RTI) caused by Klebsiella pneumoniae DT-S in mice. A single oral dose of LB 20304a (1.2mg/mouse) showed a rapid bacteriocidal activity in lung tissue at 4,7 and 24h after administration of drug. The in vivo activity of LB20304a was comparable to that of ciprofloxacin against K. pneumoniae infection, although in vitro MIC of LB20304a was four-fold higher than that of ciprofloxacin.

Keywords